ch3biosystems2024年價(jià)格表
CH3 BioSystems是一家生物技術(shù)公司，基于一種全新的受專li保護(hù)的化學(xué)技術(shù)，旨在識(shí)別和商業(yè)化候選藥物和診斷藥物。
我們制造促進(jìn)生物醫(yī)學(xué)研究的新型分子工具。我們的目標(biāo)是更好地了解影響全球數(shù)百萬(wàn)人的癌癥、自身免疫疾病、神經(jīng)發(fā)育疾病、病毒性疾病和心血管疾病。
我們的長(zhǎng)期愿景是促進(jìn)基于蛋白質(zhì)甲基化生物學(xué)新興領(lǐng)域的診斷和藥物產(chǎn)品的開發(fā)。
特別告知：為保證產(chǎn)品質(zhì)量與良好性能，所以在購(gòu)買相應(yīng)產(chǎn)品的同時(shí)我司會(huì)收取一定量的運(yùn)輸費(fèi)用！！！本次報(bào)價(jià)有效時(shí)間為2024年1月5日---2024年12月14日。
| 貨號(hào) | 品名 | 規(guī)格 | 價(jià)格 | 品牌 | 貨期 | 價(jià)格來源 |
| 92C001 | Human Embryonic Kidney (HEK) - Corporate | Vial | 16074.56 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 800001 | Methylarginine-specific antibody | 20mg | 4554.46 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 800002 | Methylarginine-specific antibody | 100mg | 8653.47 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 810001 | Control antibody reagent | 20mg | 3188.12 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 810002 | Control antibody reagent | 100mg | 5009.91 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 150001 | IgY Anti-2B | 100ml | 6376.24 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 150002 | IgY Anti-DEx3 | 100ml | 6376.24 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 150003 | IgY Anti-survivin | 100ml | 6376.24 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 150004 | IgY Anti-survivin 3B | 100ml | 6376.24 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 820001 | Type I Arginine methyltransferase | 200ml | 26415.86 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 820002 | Type III Arginine methyltransferase | 200ml | 42811.92 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 830001 | Methylation substrate | 10mg | 3370.30 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 830002 | Methylation substrate | 25mg | 5592.88 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 890001 | Methyl donor | 500ml | 2732.68 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 91A001 | PC12 pheochromocytoma | Vial | 7196.05 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91C001 | PC12 pheochromocytoma - Corporate | Vial | 21432.75 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91A002 | PC12-C41 variant PC12 cell line | Vial | 7196.05 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91C002 | PC12-C41 variant PC12 cell line - Corporate | Vial | 21432.75 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91A003 | PC12Mn variant PC12 cell line | Vial | 7196.05 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91C003 | PC12Mn variant PC12 cell line - Corporate | Vial | 21432.75 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 92A001 | Human Embryonic Kidney (HEK) | Vial | 5920.80 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 92AP01 | Human Embryonic Kidney (HEK) -Premium | Vial | 9108.92 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 93A001 | HepG2 hepatocellular carcinoma | Vial | 5920.80 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 93AP01 | HepG2 hepatocellular carcinoma - Premium | Vial | 9108.92 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 93C001 | HepG2 hepatocellular carcinoma - Corporate | Vial | 16074.56 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94A001 | E0771 breast adenocarcinoma | Vial | 8198.03 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94AP01 | E0771 breast adenocarcinoma - Premium | Vial | 18217.84 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94C001 | E0771 breast adenocarcinoma - Corporate | Vial | 139312.88 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94A002 | LNCaP Human prostate cancer | Vial | 6376.24 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94AP02 | LNCaP Human prostate cancer - Premium | Vial | 9108.92 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94C002 | LNCaP Human prostate cancer - Corporate | Vial | 16074.56 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94A003 | HeLa Human cervical cancer | Vial | 6376.24 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94AP03 | HeLa Human cervical cancer - Premium | Vial | 13663.38 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94C003 | HeLa Human cervical cancer - Corporate | Vial | 18217.84 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94A012 | PC-3 | Vial | 6376.24 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94AP12 | PC-3 - Premium | Vial | 9108.92 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94C012 | PC-3 - Corporate | Vial | 16074.56 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 99A001 | Rat tail collagen | 1ml | 4536.24 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 99A002 | Cell Sep | ea | 3279.21 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 870001 | Inhibitor A | 100ml | 1457.43 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 870002 | Inhibitor A | 500ml | 3279.21 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 880001 | Inhibitor B | 1ml | 1457.43 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 880002 | Inhibitor B | 5ml | 3279.21 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 840001 | Low ionic strength buffer | 100ml | 261.38 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 860001 | High capacity buffer | 100ml | 261.38 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110000 | pLuc Reporter Vector | ea | 2700.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110001 | LucNeo | ea | 3600.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110002 | Hsp-6270 | ea | 5980.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110003 | Hsp-3569neo | ea | 5980.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110004 | Hsp-3338neo | ea | 5980.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
（*此為部分產(chǎn)品價(jià)格完整價(jià)格請(qǐng)下載文件）
關(guān)鍵詞：ch3biosystems、甲基精氨酸特異性抗體、甲基蛋白、ch3biosystems 92C001、ch3biosystems 150001
